Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice.
González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E. González-Mariscal I, et al. Among authors: gomez canas m. Pharmacol Res. 2021 Jul;169:105492. doi: 10.1016/j.phrs.2021.105492. Epub 2021 May 19. Pharmacol Res. 2021. PMID: 34019978
Corrigendum to "Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile" [Pharmacol. Res. 110 (August 2016) (2016) 205-215].
Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR. Gómez-Cañas M, et al. Pharmacol Res. 2017 Jun;120:302. doi: 10.1016/j.phrs.2017.04.002. Epub 2017 Apr 20. Pharmacol Res. 2017. PMID: 28433484 No abstract available.
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.
del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. del Río C, et al. Sci Rep. 2016 Feb 18;6:21703. doi: 10.1038/srep21703. Sci Rep. 2016. PMID: 26887982 Free PMC article.
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.
Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C, López-Pedrera C, Appendino G, Calzado MA, Muñoz E. Del Rio C, et al. Br J Pharmacol. 2018 Oct;175(19):3813-3831. doi: 10.1111/bph.14450. Epub 2018 Aug 23. Br J Pharmacol. 2018. PMID: 30033591 Free PMC article.
Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holzgrabe U. Götz MR, et al. Among authors: gomez canas m. Front Pharmacol. 2019 Nov 20;10:1284. doi: 10.3389/fphar.2019.01284. eCollection 2019. Front Pharmacol. 2019. PMID: 31824305 Free PMC article.
Δ9 -Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors.
Palomares B, Garrido-Rodriguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saen-Oon S, Soliva R, Collado JA, Fernández-Ruiz J, Morello G, Calzado MA, Appendino G, Muñoz E. Palomares B, et al. Among authors: gomez canas m. Br J Pharmacol. 2020 Sep;177(17):4034-4054. doi: 10.1111/bph.15155. Epub 2020 Jul 8. Br J Pharmacol. 2020. PMID: 32510591 Free PMC article.
Prospects for cannabinoid therapies in basal ganglia disorders.
Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Fernández-Ruiz J, et al. Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Br J Pharmacol. 2011. PMID: 21545415 Free PMC article. Review.
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA. Deiana V, et al. Eur J Med Chem. 2016 Apr 13;112:66-80. doi: 10.1016/j.ejmech.2016.02.005. Epub 2016 Feb 6. Eur J Med Chem. 2016. PMID: 26890113
32 results